Brian N. Cherry - 12 Jan 2026 Form 4 Insider Report for Zymeworks Inc. (ZYME)

Reporting relationship: Director
Issuer ticker: ZYME
Reported as of: 12 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jan 2026, 16:30:03 UTC
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Daniel Dex, Attorney-in-Fact

Key filing fact

Brian N. Cherry filed Form 4 for Zymeworks Inc. (ZYME) on 13 Jan 2026.

Key facts

This page summarizes Brian N. Cherry's Form 4 filing for Zymeworks Inc. (ZYME).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 13 Jan 2026, 16:30.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001290922 Primary reporting owner

Cherry Brian N

Relationship: Director
Address: C/O ZYMEWORKS INC., 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN
Signature: /s/ Daniel Dex, Attorney-in-Fact
Signature date: 13 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZYME transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +23,000
Change %
Price: $0.000000
Shares after: 23,000
Date: 12 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,000
Exercise price: $23.16
Footnotes: F1

ZYME transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +15,400
Change %
Price: $0.000000
Shares after: 15,400
Date: 12 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,400
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Stock options vest in 36 equal monthly installments starting one month after grant date of January 12, 2026.

Footnote F2

Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock.

Footnote F3

RSUs vest in three equal annual installments beginning on first anniversary of grant date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .